Acanthas Pharma, Inc., Montréal, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation II SCSp.
Acanthas is developing an oral small molecule targeting a mutation involved in multiple cancers, in particular Acute Myeloid Leukemia, sarcomas and gliomas